Clinical Trials Logo

Rhinitis, Allergic clinical trials

View clinical trials related to Rhinitis, Allergic.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06462417 Not yet recruiting - Allergic Rhinitis Clinical Trials

Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis

Start date: June 20, 2024
Phase: N/A
Study type: Interventional

The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.

NCT ID: NCT06459219 Not yet recruiting - Allergic Rhinitis Clinical Trials

Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects

AllergyAge
Start date: October 1, 2024
Phase:
Study type: Observational

Nasal allergen study in patients aged 60+ with or without current respiratory allergy

NCT ID: NCT06427577 Not yet recruiting - Rhinitis, Allergic Clinical Trials

Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites

Start date: June 1, 2024
Phase: Phase 4
Study type: Interventional

ZhenQi FuZheng granules has been used to improve the immune function of human body, protect the bone marrow and adrenal cortex function and promote the recovery of positive function in traditional Chinese medicine care, especially with the immune imbalance diseases like post-surgery, chemotherapy and rhinitis. This project intends to establish AR(allergic rhinitis)specimen library, cell and animal model experiment, combining clinical cohort research with applied basic research, further assess the therapeutic mechanism of ZhenQiFuZheng granules in AR. We assume that ZhenQi FuZheng granules could cause the metabolic omics changes of nasal inflammatory factors and nasal secretions in AR patients, thus improving the type 2 inflammation level of allergic rhinitis.

NCT ID: NCT06372184 Not yet recruiting - Rhinitis, Allergic Clinical Trials

Washed Microbiota Transplantation for Allergic Rhinitis

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.

NCT ID: NCT06330974 Not yet recruiting - Asthma Clinical Trials

Allergy, Asthma, and Atopic Eczema in Finland

FinnATOPY
Start date: October 2024
Phase:
Study type: Observational [Patient Registry]

The summary is available at --> https://www.finnatopy.fi/summary

NCT ID: NCT06315426 Not yet recruiting - Allergic Rhinitis Clinical Trials

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Start date: March 2024
Phase: Phase 2
Study type: Interventional

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

NCT ID: NCT06300203 Not yet recruiting - Clinical trials for Seasonal Allergic Rhinitis

Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

MEGREZ
Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.

NCT ID: NCT06272409 Not yet recruiting - Allergic Rhinitis Clinical Trials

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

SIERRA
Start date: February 15, 2025
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DEP114 in the treatment of Moderate to Severe Persistent Allergic Rhinitis in children aged between 6 and 11 years.

NCT ID: NCT06171074 Not yet recruiting - Clinical trials for Seasonal Allergic Rhinitis

Study of CM310 in Subjects With Seasonal Allergic Rhinitis

Start date: March 30, 2024
Phase: Phase 2
Study type: Interventional

This study is a multicenter, single arm phase II clinical study mainly evaluating the efficacy of CM310 in patients with seasonal allergic rhinitis.

NCT ID: NCT05908721 Not yet recruiting - Allergic Rhinitis Clinical Trials

Study of CM310 in Patients With Allergic Rhinitis

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.